Max Ettinger1, Peter Savov2, Tilman Calliess2, Henning Windhagen2, Ralf Lichtinghagen3, Alexander Lukasz4, Mohamed Omar5. 1. Department of Orthopaedic Surgery, Hannover Medical School, Anna-von-Borries-Straße 1-7, 30625, Hannover, Germany. max@ettinger.info. 2. Department of Orthopaedic Surgery, Hannover Medical School, Anna-von-Borries-Straße 1-7, 30625, Hannover, Germany. 3. Department of Medicine D, Division of General Internal Medicine, Nephrology, and Rheumatology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Munster, Germany. 4. Department of Laboratory Medicine, Hannover Medical School, Carl-Neuberg Strasse 1, 30625, Hannover, Germany. 5. Department of Trauma Surgery, Hannover Medical School, Carl-Neuberg Strasse 1, 30625, Hannover, Germany.
Abstract
BACKGROUND: The diagnosis of low-grade periprosthetic joint infections (PJIs) is challenging, because patients may present with unspecific symptoms, false-negative cultures, or marginally elevated values of serum biomarkers like C-reactive protein (CRP). This may lead to the unintended implantation of a revision prosthesis into an infected surgical site with a repeat risk of short-term failure. Conversely, false diagnosis of joint infection may result in multistage revision procedures, which expose the patient to unnecessary surgical procedures and inappropriate antibiotic treatment. Here, we investigated whether synovial biomarkers can preoperatively distinguish between aseptic prosthesis loosening and low-grade joint infection and the most accurate biomarker combinations. METHODS: Inclusion criteria for the study were indication for revision arthroplasty due to aseptic implant failure, acute high-grade infection, or (suspected) low-grade infection. We prospectively collected synovial fluid of patients undergoing revision arthroplasty for quantitative measurement of alpha defensin, CRP, interleukin (IL-6), IL-10, and lipopolysaccharide binding protein (LBP). RESULTS: The classification tree method revealed alpha defensin and CRP as the most suitable biomarker combination to distinguish between aseptic loosening and low-grade joint infection. The combination of CRP > 2.0 mg/L and alpha defensin > 90.000 pg/mL correctly identified nine of 11 patients with low-grade infection. CONCLUSIONS: Alpha defensin plus CRP seems to be the most helpful combination for pre-operative discrimination of aseptic loosening vs. low-grade joint infection.
BACKGROUND: The diagnosis of low-grade periprosthetic joint infections (PJIs) is challenging, because patients may present with unspecific symptoms, false-negative cultures, or marginally elevated values of serum biomarkers like C-reactive protein (CRP). This may lead to the unintended implantation of a revision prosthesis into an infected surgical site with a repeat risk of short-term failure. Conversely, false diagnosis of joint infection may result in multistage revision procedures, which expose the patient to unnecessary surgical procedures and inappropriate antibiotic treatment. Here, we investigated whether synovial biomarkers can preoperatively distinguish between aseptic prosthesis loosening and low-grade joint infection and the most accurate biomarker combinations. METHODS: Inclusion criteria for the study were indication for revision arthroplasty due to aseptic implant failure, acute high-grade infection, or (suspected) low-grade infection. We prospectively collected synovial fluid of patients undergoing revision arthroplasty for quantitative measurement of alpha defensin, CRP, interleukin (IL-6), IL-10, and lipopolysaccharide binding protein (LBP). RESULTS: The classification tree method revealed alpha defensin and CRP as the most suitable biomarker combination to distinguish between aseptic loosening and low-grade joint infection. The combination of CRP > 2.0 mg/L and alpha defensin > 90.000 pg/mL correctly identified nine of 11 patients with low-grade infection. CONCLUSIONS: Alpha defensin plus CRP seems to be the most helpful combination for pre-operative discrimination of aseptic loosening vs. low-grade joint infection.
Authors: Andrej Trampuz; Kerryl E Piper; Melissa J Jacobson; Arlen D Hanssen; Krishnan K Unni; Douglas R Osmon; Jayawant N Mandrekar; Franklin R Cockerill; James M Steckelberg; James F Greenleaf; Robin Patel Journal: N Engl J Med Date: 2007-08-16 Impact factor: 91.245
Authors: Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson Journal: Clin Infect Dis Date: 2012-12-06 Impact factor: 9.079
Authors: Carl Deirmengian; Keith Kardos; Patrick Kilmartin; Alexander Cameron; Kevin Schiller; Javad Parvizi Journal: J Bone Joint Surg Am Date: 2014-09-03 Impact factor: 5.284
Authors: Kerryl E Piper; Marta Fernandez-Sampedro; Kathryn E Steckelberg; Jayawant N Mandrekar; Melissa J Karau; James M Steckelberg; Elie F Berbari; Douglas R Osmon; Arlen D Hanssen; David G Lewallen; Robert H Cofield; John W Sperling; Joaquin Sanchez-Sotelo; Paul M Huddleston; Mark B Dekutoski; Michael Yaszemski; Bradford Currier; Robin Patel Journal: PLoS One Date: 2010-02-22 Impact factor: 3.240
Authors: Steven M Kurtz; Edmund Lau; Kevin Ong; Ke Zhao; Michael Kelly; Kevin J Bozic Journal: Clin Orthop Relat Res Date: 2009-04-10 Impact factor: 4.176
Authors: Carl Deirmengian; Keith Kardos; Patrick Kilmartin; Alexander Cameron; Kevin Schiller; Robert E Booth; Javad Parvizi Journal: Clin Orthop Relat Res Date: 2015-01 Impact factor: 4.176
Authors: Ze Yu Huang; Qiang Huang; Li Ying Wang; Yi Ting Lei; Hong Xu; Bin Shen; Fu Xing Pei Journal: BMC Musculoskelet Disord Date: 2020-04-21 Impact factor: 2.362